January 27, 2011
On Nov. 13, 2007, the media widely published the news that several HIV transmissions had resulted after donated organs were transplanted from a deceased high-risk donor. Though this was the first such transmission in 20 years, it prompted an "exaggerated" response by some US transplant surgeons, a new study suggests.
CDC-defined high-risk organ donors (HRDs) include those who, in the past five years, have engaged in specific risk behaviors: men having sex with men, drug injecting, and sex work.
Between January and April 2008, researchers surveyed 422 working US transplant surgeons about their attitudes and practices following the 2007 transmission event.
"The risk of death while waiting for an organ transplant is far higher for many patients than is the risk associated with these organs," said study leader Dr. Dorry Segev of the Johns Hopkins University School of Medicine.
In 2009, 14,600 people donated organs, and about 6,700 people died waiting for such a donation. More than 72,000 Americans are on a waiting list for organs.
The 2007 transmission case involved donated organs from a man who had sex with men. Standard antibody tests for hepatitis C and HIV came back negative, and his organs were transplanted into four recipients, who later turned up infected with both viruses. NAT, which can detect more recent HIV infections than antibody tests, is now used at the organ procurement center that distributed the organs in the 2007 case.
The study, "Provider Response to a Rare but Highly Publicized Transmission of HIV Through Solid Organ Transplantation," was published in the Archives of Surgery (2011;146(1):41-45).
01.17.2011; Carla K. Johnson
No comments have been made.
|Taking Atripla Three Days a Week Maintains Undetectable HIV Viral Load, Pilot Study Finds|
|Which HIV Treatment Regimens Are Recommended for Newly Diagnosed Patients?|
|Weekly PRO 140 Antibody Injections May Work as HIV Maintenance Therapy|
|This Week in HIV Research: Effects of Treatment on Arterial Inflammation; Mortality Rate After 5 Years of Treatment Not Impacted by Initial CD4 Count|
|Investigational Integrase Inhibitor Bictegravir Safe and Effective Against HIV in Early Study|